Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Lancet. 2012 Jan 28;379(9813):335-41. doi: 10.1016/S0140-6736(11)61266-X. Epub 2011 Nov 29.
The interest in neonatal screening for lysosomal storage disorders has increased substantially because of newly developed enzyme replacement therapies, the need for early diagnosis, and technical advances. We tested for Gaucher's disease, Pompe's disease, Fabry's disease, and Niemann-Pick disease types A and B in an anonymous prospective nationwide screening study that included genetic mutation analysis to assess the practicality and appropriateness of including these disorders in neonatal screening panels.
Specimens from dried blood spots of 34,736 newborn babies were collected consecutively from January, 2010 to July, 2010, as part of the national routine Austrian newborn screening programme. Anonymised samples were analysed for enzyme activities of acid β-glucocerebrosidase, α-galactosidase, α-glucosidase, and acid sphingomyelinase by electrospray ionisation tandem mass spectrometry. Genetic mutation analyses were done in samples with suspected enzyme deficiency.
All 34,736 samples were analysed successfully by the multiplex screening assay. Low enzyme activities were detected in 38 babies. Mutation analysis confirmed lysosomal storage disorders in 15 of them. The most frequent mutations were found for Fabry's disease (1 per 3859 births), followed by Pompe's disease (1 per 8684), and Gaucher's disease (1 per 17,368). The positive predictive values were 32% (95% CI 16-52), 80% (28-99), and 50% (7-93), respectively. Mutational analysis detected predominantly missense mutations associated with a late-onset phenotype.
The combined overall proportion of infants carrying a mutation for lysosomal storage disorders was higher than expected. Neonatal screening for lysosomal storage disorders is likely to raise challenges for primary health-care providers. Furthermore, the high frequency of late-onset mutations makes lysosomal storage disorders a broad health problem beyond childhood.
Austrian Ministry of Health, Family, and Women.
由于新开发的酶替代疗法、早期诊断的需求以及技术进步,人们对新生儿进行溶酶体贮积症筛查的兴趣大大增加。我们在一项匿名的全国前瞻性筛查研究中检测了戈谢病、庞贝病、法布雷病、尼曼-匹克病 A 型和 B 型,其中包括基因突变分析,以评估将这些疾病纳入新生儿筛查组的实用性和适当性。
2010 年 1 月至 7 月,作为国家常规奥地利新生儿筛查计划的一部分,连续采集了 34736 名新生儿干血斑样本。通过电喷雾串联质谱法对酸性β-葡糖脑苷脂酶、α-半乳糖苷酶、α-葡萄糖苷酶和酸性鞘磷脂酶的酶活性进行分析。对疑似酶缺乏的样本进行基因突变分析。
通过多重筛选检测成功分析了所有 34736 个样本。在 38 名婴儿中发现了低酶活性。基因突变分析在其中 15 名证实为溶酶体贮积症。最常见的突变发生在法布雷病(每 3859 例出生 1 例),其次是庞贝病(每 8684 例)和戈谢病(每 17368 例)。阳性预测值分别为 32%(95%CI 16-52)、80%(28-99)和 50%(7-93)。突变分析主要检测到与迟发性表型相关的错义突变。
携带溶酶体贮积症突变的婴儿总数高于预期。新生儿溶酶体贮积症筛查可能会给初级保健提供者带来挑战。此外,迟发性突变的高频率使得溶酶体贮积症成为儿童期以外的广泛健康问题。
奥地利卫生部、家庭和妇女部。